BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results

Pharmaceutical Investing

BioDelivery Sciences International (NASDAQ:BDSI) today reported financial results for the fourth quarter and year ended December 31, 2017 and provided an update on recent business highlights. As quoted in the press release: “We achieved strong revenue growth in both the fourth quarter and full-year 2017, driven by continued BELBUCA prescription growth,” said Scott M. Plesha, …

BioDelivery Sciences International (NASDAQ:BDSI) today reported financial results for the fourth quarter and year ended December 31, 2017 and provided an update on recent business highlights.

As quoted in the press release:

“We achieved strong revenue growth in both the fourth quarter and full-year 2017, driven by continued BELBUCA prescription growth,” said Scott M. Plesha, President of BioDelivery Sciences. “For full-year 2017, we recorded BELBUCA prescription growth of 84% over 2016. The momentum we experienced with BELBUCA in 2017 has extended into 2018, as we reached an all-time high in monthly prescriptions of over 8,600 prescriptions in January and are on track for strong results in February following the highest 4-week total in prescriptions we have seen to date. We believe that BDSI is well-positioned to continue our growth trend with BELBUCA, as we have increased the size of our sales force, undertaken new marketing initiatives and achieved significant progress with new and improved managed care contracts.”

Click here to read the full press release.

biodelivery sciences financial results Pharmaceutical Investing